Status:
UNKNOWN
Diagnosis of Nodules ≤2 cm Based on US and CEUS Compared With Current Clinical Procedure
Lead Sponsor:
Tianjin Third Central Hospital
Collaborating Sponsors:
Tianjin Second People's Hospital
Tianjin Medical University Cancer Institute and Hospital
Conditions:
Liver Cancer
Liver Cirrhosis
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Due to different etiologies, diagnosis and treatment of HCC in China is different from that in Western countries.US is an important screening method for HCC in patients with liver cirrhosis. CEUS, as ...
Eligibility Criteria
Inclusion
- Patients are at high risk of HCC.
- The ages of patients are between 18 and 80.
- Patients are with solid liver lesion(s) ≤ 2 cm detected by US.
- Patient signs the informed consent.
Exclusion
- Patients are with liver cirrhosis due to congenital hepatic fibrosis or due to hepatic vascular diseases such as hereditary telangiectasia, Budd-Chiari syndrome, chronic portal vein occlusion syndrome, congestive heart disease.
- Patient's age is \< 18 years old or \> 80 years old.
- Patients with known hypersensitivity to CEUS, CECT, CEMRI, or hepatobiliary-specific MRI contrast agents.
- Patient is a pregnant or breastfeeding woman.
- Patient is not diagnosed based on the reference diagnostic criteria required by the study.
- Patient is considered to be unsuitable to participate in the study.
Key Trial Info
Start Date :
October 26 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
6730 Patients enrolled
Trial Details
Trial ID
NCT05360420
Start Date
October 26 2022
End Date
December 31 2024
Last Update
December 13 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tianjin Third Central Hospital
Tianjin, Tianjin Municipality, China, 300170